A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

NCT06650852 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B Virus (HBV) Infection

Interventions

BIOLOGICAL: BRII-179
DRUG: BRII-835 (VIR-2218)
BIOLOGICAL: PEG-IFNα
DRUG: Placebo of BRII-179
DRUG: Placebo of BRII-835

Sponsor

Brii Biosciences Limited